Palatin takes front seat in merger with Molecular Biosystems
This article was originally published in Clinica
Executive Summary
Molecular Biosystems, maker of the FDA-approved Optison ultrasound contrast imaging agent, is to merge with a development-stage imaging agent company, Palatin Technologies, in a stock transaction valued at around $30 million. Upon completion, Palatin shareholders and the shareholders of Mallinckrodt, which has distribution arrangements and an equity stake in both companies, will each have around 50% of the new company.